ArticleKidney3602026
Novel Molecular Signatures of Peripheral Regulatory T Cells in Kidney Disease Associated with Type 1 Diabetes.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Erosion of Immune Regulation in Diabetic Kidney Disease.Kidney360 · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
key pointsRegulatory T cells (Tregs) from people (control, type 1 diabetes with and without albuminuria) were profiled for phenotypic and transcriptomic changes. Central memory Tregs were reduced, while Treg EMRA + cells were higher in type 1 diabetes with albuminuria. In silico findings suggest potential interactions between Treg ligand and kidney cell receptor at transcript level.
backgroundDiabetic kidney disease (DKD) is a common complication of type 1 diabetes (T1D). T1D and some kidney disorders are often associated with abnormalities in regulatory T cells (Tregs). However, it is unknown if Treg subsets and their molecular architecture are altered during the onset and progression of DKD in T1D.
methodsWe addressed this critical knowledge gap by characterizing changes in Tregs isolated from 31 participants (10 control, 13 with T1D, and eight T1D with albuminuria) using flow cytometry, RNA-sequencing, and microRNA profiling.
resultsWe identified that the effector and central memory Tregs were significantly different between groups. Similarly, multiple gene transcripts were also significantly different between groups that also overlapped with other publicly available datasets. Machine learning-based data analyses discovered a set of important microRNAs associated with clinical eGFR values. Importantly, our analyses identified two differentially expressed Treg ligand genes (leucine rich repeat containing 4B, transglutaminase-2), which interacted with the receptors on kidney cells (protein tyrosine phosphatase receptor type D/F/S, Adhesion G Protein-Coupled Receptor G1; a.k.a GPR56) in silico , providing potential mechanistic insights into the role of Tregs in DKD progression.
conclusionsTogether, our work supports the yet unappreciated role of Tregs in DKD and opens new research avenues to further consolidate their causal relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.